Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency

Growth Hormone and IGF Research

Volumn 21, Issue 2, 2011, Pages 69-75

  Jorgensen A P ^a   Fougner, K J ^b   Ueland, T ^a,c   Gudmundsen, O ^d   Burman, P ^e   Schreiner, T ^a   Bollerslev, J ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Link Medical Research AS   (Norway)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Body composition; Bone mineral density; GH deficiency; Growth hormone; Insulin; Lipids; Quality of life

Indexed keywords

GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS; BODY COMPOSITION; BODY FAT; BODY MASS; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; EDEMA; FEMALE; FEMUR; FOLLOW UP; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HOPKINS SYMPTOM CHECKLIST 58; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOPHYSIS ADENOMA; INSULIN BLOOD LEVEL; LIPID ANALYSIS; LUMBAR SPINE; MALE; MENINGITIS; MYALGIA; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; SHORT FORM 36; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BODY COMPOSITION; BONE AND BONES; BONE DENSITY; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; LIPIDS; MALE; QUALITY OF LIFE; TIME;

EID: 79955481843     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2011.01.001     Document Type: Article

References (46)

1. Stochholm K., Gravholt C.H., Laursen T., et al. Incidence of GH deficiency - a nationwide study. Eur. J. Endocrinol. 2006, 155:61-71.
2. Rosen T., Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336:285-288.
3. Bulow B., Hagmar L., Mikoczy Z., et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. Oxf. 1997, 46:75-81.
4. Bates A.S., Van't H.W., Jones P.J., et al. The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. 1996, 81:1169-1172.
5. Tomlinson J.W., Holden N., Hills R.K., et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001, 357:425-431.
6. Stochholm K., Laursen T., Green A., et al. Morbidity and GH deficiency: a nationwide study. Eur. J. Endocrinol. 2008, 158:447-457.
7. Carroll P.V., Christ E.R., Bengtsson B.A., et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 1998, 83:382-395.
8. Molitch M.E., Clemmons D.R., Malozowski S., et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2006, 91:1621-1634.
9. Johansson J.O., Fowelin J., Landin K., et al. Growth hormone-deficient adults are insulin-resistant. Metabolism 1995, 44:1126-1129.
10. Burman P., Deijen J.B. Quality of life and cognitive function in patients with pituitary insufficiency. Psychother. Psychosom. 1998, 67:154-167.
11. Gotherstrom G., Bengtsson B.A., Bosaeus I., et al. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J. Clin. Endocrinol. Metab. 2007, 92:1442-1445.
12. Gotherstrom G., Bengtsson B.A., Bosaeus I., et al. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur. J. Endocrinol. 2007, 156:55-64.
13. Gotherstrom G., Elbornsson M., Stibrant-Sunnerhagen K., et al. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J. Clin. Endocrinol. Metab. 2009, 94:809-816.
14. Gibney J., Wallace J.D., Spinks T., et al. The effects of 10years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 1999, 84:2596-2602.
15. Monson J.P. Long-term experience with GH replacement therapy: efficacy and safety. Eur. J. Endocrinol. 2003, 148(Suppl. 2):S9-S14.
16. Giavoli C., Porretti S., Ronchi C.L., et al. Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. Metabolism 2004, 53:740-743.
17. Al-Shoumer K.A., Gray R., Anyaoku V., et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin. Endocrinol. Oxf. 1998, 48:795-802.
18. Christopher M., Hew F.L., Oakley M., et al. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24months of recombinant human growth hormone therapy. J. Clin. Endocrinol. Metab. 1998, 83:1668-1681.
19. Attanasio A.F., Mo D., Erfurth E.M., et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J. Clin. Endocrinol. Metab. 2010, 95:74-81.
20. Koranyi J., Svensson J., Gotherstrom G., et al. Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study. J. Clin. Endocrinol. Metab. 2001, 86:4693-4699.
21. Arwert L.I., Roos J.C., Lips P., et al. Effects of 10years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin. Endocrinol. Oxf. 2005, 63:310-316.
22. van der Klaauw A.A., Romijn J.A., Biermasz N.R., et al. Sustained effects of recombinant GH replacement after 7years of treatment in adults with GH deficiency. Eur. J. Endocrinol. 2006, 155:701-708.
23. Bollerslev J., Hallen J., Fougner K.J., et al. Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial. Eur. J. Endocrinol. 2005, 153:379-387.
24. Derogatis L.R., Lipman R.S., Rickels K., et al. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav. Sci. 1974, 19:1-15.
25. Jenkinson C., Coulter A., Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993, 306:1437-1440.
26. McKenna S.P., Doward L.C., Alonso J., et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual. Life Res. 1999, 8:373-383.
27. Svensson J., Mattsson A., Rosen T., et al. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Horm. IGF Res. 2004, 14:207-215.
28. Godang K., Ueland T., Bollerslev J. Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome. Eur. J. Endocrinol. 1999, 141:126-131.
29. Koltowska-Haggstrom M., Mattsson A.F., Monson J.P., et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?. Eur. J. Endocrinol. 2006, 155:109-119.
30. de B.H., Blok G.J., van L.A., et al. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J. Bone Miner. Res. 1994, 9:1319-1326.
31. Toogood A.A., Adams J.E., O'Neill P.A., et al. Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J. Clin. Endocrinol. Metab. 1997, 82:1462-1466.
32. Rosen T., Hansson T., Granhed H., et al. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta. Endocrinol. Copenh. 1993, 129:201-206.
33. Rosen T., Wilhelmsen L., Landin-Wilhelmsen K., et al. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur. J. Endocrinol. 1997, 137:240-245.
34. Holmer H., Svensson J., Rylander L., et al. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J. Bone Miner. Res. 2007, 22:1842-1850.
35. Brixen K., Nielsen H.K., Mosekilde L., et al. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J. Bone Miner. Res. 1990, 5:609-618.
36. Hansen T.B., Brixen K., Vahl N., et al. Effects of 12months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 1996, 81:3352-3359.
37. Bravenboer N., Holzmann P.J., ter Maaten J.C., et al. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J. Bone Miner. Res. 2005, 20:1778-1784.
38. Valimaki M.J., Salmela P.I., Salmi J., et al. Effects of 42months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur. J. Endocrinol. 1999, 140:545-554.
39. Davidson P., Milne R., Chase D., et al. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin. Endocrinol. Oxf. 2004, 60:92-98.
40. Clanget C., Seck T., Hinke V., et al. Effects of 6years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin. Endocrinol. Oxf. 2001, 55:93-99.
41. Murray R.D., Columb B., Adams J.E., et al. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J. Clin. Endocrinol. Metab. 2004, 89:1124-1130.
42. Ueland T., Bollerslev J., Flyvbjerg A., et al. Effects of 12months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 2002, 87:2760-2763.
43. Yuen K.C., Dunger D.B. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diab. Obes. Metab. 2007, 9:11-22.
44. Chrisoulidou A., Beshyah S.A., Rutherford O., et al. Effects of 7years of growth hormone replacement therapy in hypopituitary adults. J. Clin. Endocrinol. Metab. 2000, 85:3762-3769.
45. Monson J.P., Jonsson P., Koltowska-Haggstrom M., et al. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin. Endocrinol. Oxf. 2007, 67:623-628.
46. Attanasio A.F., Lamberts S.W., Matranga A.M., et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J. Clin. Endocrinol. Metab. 1997, 82:82-88.